The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo

Immunology

Volumn 111, Issue 3, 2004, Pages 291-297

  Imai, Masaki ^a   Hwang, Hee Young ^a   Norris, James S ^a   Tomlinson, Stephen ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BUFFER; COMPLEMENT; COMPLEMENT INHIBITOR DECAY ACCELERATING FACTOR; DEXAMETHASONE; MUCIN 1; MUCIN 1 ANTIBODY; PHOSPHATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; UPREGULATION;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CLUSTERIN; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DEXAMETHASONE; FLOW CYTOMETRY; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR CHAPERONES; MUCINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 1642355766     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0019-2805.2004.01815.x     Document Type: Article

References (35)

1. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 1998; 4:397-403.
2. Denda-Nagai K, Irimura T. MUC1 in carcinoma-host interactions. Glycoconj J 2000; 17:649-58.
3. Rye PD, Price M, Petrakou E et al. International workshop on monoclonal antibodies against MUC1. Tumor Biol 1998; 19:1-152.
4. Treon SP, Mollick JA, Urashima M et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999; 93:1287-98.
5. Schut IC, Waterfall PM, Ross M, O'Sullivan C, Miller WR, Habib FK, Bayne CW. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue. Brit J Urol Int 2003; 91:278-83.
6. Tsarfaty I, Hareuveni M, Horev J et al. Isolation and characterization of an expressed hypervariable gene coding for a breast-cancer-associated antigen. Gene 1990; 93:313-8.
7. Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitriou J, Gendler SJ. Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem Biophys Res Commun 1990; 173:1019-29.
8. Yu J, Abagyan RA, Dong S, Gilbert A, Nussenzweig V, Tomlinson S. Mapping the active site of CD59. J Exp Med 1997; 185:745-53.
9. Okada N, Harada R, Fujita T, Okada H. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol 1989; 143:2262-6.
10. Coyne KE, Hall SE, Thompson S et al. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992; 149:2906-13.
11. Yu J, Caragine T, Chen S, Morgan BP, Frey AF, Tomlinson S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin Exp Immunol 1999; 115:13-8.
12. Yu J, Dong S, Rushmere NK, Morgan BP, Abagyan R, Tomlinson S. Mapping the regions of the complement inhibitor CD59 responsible for its species selectivity. Biochemistry 1997; 36:9423-8.
13. Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates DAF expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000; 60:3013-118.
14. Harris CL, Spiller OB, Morgan BP. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 2000; 100:462-70.
15. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. J Immunol Meth 1989; 125:147-58.
16. Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000; 49:259-66.
17. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54.
18. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263-71.
19. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51:634-41.
20. Ollert MW, David K, Vollmert C, Juhl H, Erttmann R, Bredehorst R, Vogel CW. Mechanisms of in vivo anti-neuroblastoma activity of human natural IgM. Eur J Cancer 1997; 33:1942-8.
21. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998; 58:2844-9.
22. Blok VT, Gelderman KA, Tijsma OH, Daha MR, Gorter A. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand J Immunol 2003; 57:591-9.
23. Varsano S, Rashkovsky L, Shapiro H, Radnay J. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol 1998; 19:522-9.
24. Lappin DF, Whaley K. Modulation of complement gene expression by glucocorticoids. Biochem J 1991; 280:117-23.
25. Dauchel H, Julen N, Lemercier C, Daveau M, Ozanne D, Fontaine M, Ripoche J. Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids. Eur J Immunol 1990; 20:1669-75.
26. Friese MA, Hellwage J, Jokiranta TS, Meri S, Muller-Quernheim HJ, Peter HH, Eibel H, Zipfel PF. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121:406-15.
27. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000; 164:6075-81.
28. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000; 275: 16666-72.
29. Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 2001; 93:848-54.
30. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100:1765-73.
31. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6.
32. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998; 95:652-6.
33. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999; 42:61-74.
34. Freedland SJ, Seligson DB, Liu AY et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003; 55:71-80.
35. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000; 15:343-56.